News | August 06, 2023
Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Qualicaps is the third largest producer of hard capsules for oral dosage solutions
With an annual revenue of about $500 million, Spectrum will become part of the Industrial Solutions line of business within the Electronics & Industrial segment
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Subscribe To Our Newsletter & Stay Updated
